We spent years engineering EV2 Peptide, a next-generation biomimetic inspired by one of the most studied molecules in hair science, GHK-Cu
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
When to Talk to Your Healthcare Provider If you have concerns related to sexual health, the Melanotan II pathway, or how your MC1R rs1805008 results fit into your broader health picture, consult your healthcare provider
People often report improved blood sugar readings and substantial weight loss compared with older treatments
Specific duties include: Ready to put this into practice
Your provider will assess your medical history, current medications, and any conditions that might make GLP-1 inappropriate
-1775582746855.png&w=3840&q=75)
